Literature DB >> 9015175

Intrahepatic cholangiocarcinoma.

K M Chu1, E C Lai, S Al-Hadeedi, C E Arcilla, C M Lo, C L Liu, S T Fan, J Wong.   

Abstract

Intrahepatic cholangiocarcinoma is an uncommon neoplasm of liver compared with hepatocellular carcinoma. Hepatic resection seems to provide the only chance for therapeutic success. The records of 77 patients with intrahepatic cholangiocarcinoma treated over a 28-year period were studied to determine demographics, clinical features, laboratory findings, diagnostic tests, operative management, and results of therapy. Survival was analyzed according to three treatment groups: conservative management, palliative operation, and hepatic resection. Conservative management was used for 15 patients, and hepatic resections were performed in 39 patients. The remaining 23 patients had laparotomy alone (10 patients), bile duct intubation (4 patients), hepatic artery ligation (3 patients), bilienteric bypass (3 patients), gastrojejunostomy (1 patient), insertion of a hepatic artery port for regional chemotherapy (1 patient), or open drainage of an abscess (1 patient). The median survival after conservative management, palliative operation, and hepatic resection were 1.8, 2.9, and, 12.2 months, respectively. After hepatic resection, patients without lymphatic permeation (p < 0.02) or hilar nodal metastases (p < 0.0003) survived significantly longer. We concluded that hepatic resection is indicated for intrahepatic cholangiocarcinoma when it is deemed resectable.

Entities:  

Mesh:

Year:  1997        PMID: 9015175     DOI: 10.1007/s002689900233

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

1.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.

Authors:  Yuji Morine; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Tetsuya Ikemoto; Jun Hanaka; Mami Kanamoto; Nobuhiro Kurita; Hidenori Miyake
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

Review 2.  [Diagnostic radiology of liver tumors. Part 1: General disease aspects and radiological procedures].

Authors:  G Layer; M Bohrer
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

Review 3.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

Review 4.  Surgical management of proximal bile duct cancers.

Authors:  Jennifer LaFemina; William R Jarnagin
Journal:  Langenbecks Arch Surg       Date:  2012-03-06       Impact factor: 3.445

5.  [Surgical therapy of intrahepatic cholangiocellular carcinoma].

Authors:  H Lang; G C Sotiropoulos; E Brokalaki; N R Frühauf; J Radü; A Paul; J Wohlschlaeger; H A Baba; M Malagó; C E Broelsch
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

6.  Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Takahito Nakagawa; Toshiya Kamiyama; Nobuaki Kurauchi; Michiaki Matsushita; Kazuaki Nakanishi; Hirofumi Kamachi; Takeaki Kudo; Satoru Todo
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

7.  Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma.

Authors:  Yuji Morine; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Tetsuya Ikemoto; Hiroki Mori; Jun Hanaoka; Mami Kanamoto; Hidenori Miyake
Journal:  Surg Today       Date:  2011-11-30       Impact factor: 2.549

8.  Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma.

Authors:  Andreas Weber; Sonja Landrock; Jochen Schneider; Manfred Stangl; Bruno Neu; Peter Born; Meinhard Classen; Thomas Rösch; Roland-M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

9.  Peripheral cholangiocarcinoma with endoluminal tumor thrombus in main bile duct mimicking a Klatskin tumor.

Authors:  V Lucidi; J L Van Laethem; T Sersté; M Gelin; V Donckier
Journal:  J Gastrointest Surg       Date:  2007-09-06       Impact factor: 3.452

10.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.